Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIM ImmunoTech Inc.HEB · Entity 8131 | CFO | March 18, 2019 | June 17, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIM ImmunoTech Inc.
Report date March 18, 2019 · Filed June 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,148 |
Ending reported balance
After 2019-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-18 · Conversion · Acquired 50,000 · Balance 112,148 F1: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the ten shares issued. Row 2 · 2019-05-08 · Conversion · Acquired 35,000 · Balance 147,148 F2: Rights offering warrants using the cashless conversion feature, were converted into .70 number of shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the ten shares issued.
F2: Rights offering warrants using the cashless conversion feature, were converted into .70 number of shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2019 Filed Jun 17, 2019 15:57 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000002 · primary_doc.xml · nonDerivative · entry 2 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Rights offering warrants using the cashless conversion feature, were converted into .70 number of shares. Read SEC document |
| March 18, 2019 Filed Jun 17, 2019 15:57 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000002 · primary_doc.xml · nonDerivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the ten shares issued. Read SEC document |
| February 27, 2019 Filed Mar 12, 2019 17:40 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSubr Rights(to buy) · Derivative | 10 | $1,000.00 Strike: $1,000.00 | $10,000.00 |
DisclosureSEC source: 0001613377-19-000001 · primary_doc.xml · derivative · entry 3 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Pref Stk/Warrants · Not disclosed shares Expires 2019-03-05 F1 · derivative.underlying: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F2 · derivative.underlying: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · derivative.underlying_shares: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| February 27, 2019 Filed Mar 12, 2019 17:40 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherWarrants | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000001 · primary_doc.xml · nonDerivative · entry 2 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F2 · security: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · shares: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · price: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| February 27, 2019 Filed Mar 12, 2019 17:40 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSeries B Convertible Preferred Stock | 10 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000001 · primary_doc.xml · nonDerivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10 F1 · security: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · shares: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · price: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 15:59 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 142,046 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001450324-19-000003 · primary_doc.xml · derivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,046 Underlying: Common Stock · 142,046 shares Expires 2029-01-28 F1 · security: This option is being issued to senior management for a voluntary 50% deferral in salary. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 14:20 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001613377-18-000033 · primary_doc.xml · nonDerivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,148 F1 · kind: The Board of Directors awarded 2,500 shares of Company common stock to each employee, executive, and board member as a holiday bonus to be issued after January 2, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 15:55 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 1,000 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000028 · primary_doc.xml · derivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-11-14 F1 · security: This option has been awarded by the Board of Directors. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 14:57 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 94,697 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000021 · primary_doc.xml · derivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,697 Underlying: Common Stock · 94,697 shares Expires 2028-10-17 F1 · security: This option is being issued to senior management in exchange for a voluntary 50% deferral in salary. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 13:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 32,259 | $0.31 | $10,000.29 |
DisclosureSEC source: 0001613377-18-000017 · primary_doc.xml · nonDerivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,648 Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 16:50 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 53,763 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001613377-18-000012 · primary_doc.xml · derivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,763 Underlying: Common Stock · 53,763 shares Expires 2028-07-18 F1 · security: This option is being issued to senior management in exchange for a voluntary 40% deferral in salary. Read SEC document |
| May 16, 2018 Filed May 18, 2018 13:57 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 83,334 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001613377-18-000006 · primary_doc.xml · derivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,334 Underlying: Common Stock · 83,334 shares Expires 2028-05-16 F1 · security: This option is being issued to senior management in exchange for a voluntary 40% deferral in salary. Read SEC document |
| April 12, 2018 Filed Apr 19, 2018 17:31 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 75,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001465652-18-000003 · primary_doc.xml · derivative · entry 1 PASCALE ADAM · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-04-12 F1 · security: This option is being awarded by the Board of Directors. Read SEC document |
| February 13, 2018 Filed Mar 1, 2018 16:59 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 123,874 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001613377-18-000001 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,874 Underlying: Common Stock · 123,874 shares Expires 2028-02-13 F1 · security: This option is being issued to senior management in exchange for a voluntary 40% deferral in salary. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 16:55 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 8,155 | $0.26 Strike: $0.36 | $2,120.30 |
DisclosureSEC source: 0001613377-17-000039 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,155 Underlying: Common Stock · 8,155 shares Expires 2027-08-31 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 15:43 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 7,112 | $0.29 Strike: $0.41 | $2,062.48 |
DisclosureSEC source: 0001613377-17-000033 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112 Underlying: Common Stock · 7,112 shares Expires 2027-08-15 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 15:59 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 6,929 | $0.30 Strike: $0.42 | $2,078.70 |
DisclosureSEC source: 0001613377-17-000027 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,929 Underlying: Common Stock · 6,929 shares Expires 2027-07-31 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| July 15, 2017 Filed Jul 17, 2017 19:59 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 6,042 | $0.34 Strike: $0.48 | $2,054.28 |
DisclosureSEC source: 0001613377-17-000021 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,042 Underlying: Common Stock · 6,042 shares Expires 2027-07-15 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:02 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 4,738 | $0.44 Strike: $0.49 | $2,084.72 |
DisclosureSEC source: 0001613377-17-000015 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,738 Underlying: Common Stock · 4,738 shares Expires 2027-06-30 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:03 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 4,765 | $0.44 Strike: $0.54 | $2,096.60 |
DisclosureSEC source: 0001613377-17-000007 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,765 Underlying: Common Stock · 4,765 shares Expires 2027-06-15 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| June 15, 2017 Filed Jun 29, 2017 16:26 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 4,738 | $0.44 Strike: $0.49 | $2,084.72 |
DisclosureSEC source: 0001613377-17-000011 · primary_doc.xml · derivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,738 Underlying: Common Stock · 4,738 shares Expires 2027-06-15 F1 · security: Amendment due to salary reduction as explained in the 8-K filed on June 22, 2017. F1 · price: Amendment due to salary reduction as explained in the 8-K filed on June 22, 2017. Read SEC document |
| May 02, 2017 Filed May 2, 2017 18:09 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 15,873 | $0.63 | $9,999.99 |
DisclosureSEC source: 0001613377-17-000005 · primary_doc.xml · nonDerivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,389 Read SEC document |
| February 16, 2017 Filed Feb 21, 2017 17:33 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 6,981 | $0.46 | $3,211.26 |
DisclosureSEC source: 0001613377-17-000001 · primary_doc.xml · nonDerivative · entry 1 Pascale Adam · CIK 0001613377 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,516 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.